Talis Biomedical Corporation Stock News

Talis Biomedical Corp (TLIS) shares closed this week 23.4% lower than it did at the end of last week. The stock is currently down 20.0% year-to-date, down 88.5% over the past 12 months, and down 88.5% over the past five years. This week, the Dow Jones Industrial Average fell 1.3%, and the S&P 500 fell 2.6%. Trading Activity Shares traded as high as $4.34 and as low as $3.11 this week.Shares closed 90.5% below its 52-week high and 3.2% above its 52-week low.Trading volume this week was 24.3% lower than the 10-day average and 17.7% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 1376.8% The company's stock price performance over the past 12 months lags the peer average by 897.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Talis Biomedical Corp (TLIS) shares closed today at 1.8% above its 52 week low of $3.25, giving the company a market cap of $87M. The stock is currently down 17.5% year-to-date, down 88.1% over the past 12 months, and down 88.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 16.5% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 10.9% lower than its 5-day moving average, 17.1% lower than its 20-day moving average, and 39.6% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -8028.7% The company's stock price performance over the past 12 months lags the peer average by 961.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

LOS ANGELES, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, continues its investigation on behalf of Talis Biomedical Corporation (Talis or the Company) (NASDAQ: TLIS ) investors concerning the Companys possible violations of the federal securities laws.

(PR-inside.com) NEW YORK, NY / ACCESSWIRE / December 13, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Talis Biomedical Corporation ("Talis" or the "Company") (NASDAQ:TLIS). Investors who purchased Talis shares are encouraged to obtain additional information and assist the investigation by visiting the firm''s site: www.bgandg.com/tlis. The investigation concerns whether Talis and certain of its officers and/or directors have violated federal securities laws. On August 10, 2021, Talis reported its second quarter 2021 financial results. Discussing its results on the related earnings call, the Company revealed that its "development timelines have been extended by delays ..

LOS ANGELES--(BUSINESS WIRE)---- $TLIS #investors--The Law Offices of Frank R. Cruz Continues Its Investigation of Talis Biomedical Corporation (TLIS) on Behalf of Investors

MENLO PARK, Calif., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that Rob Kelley, the Companys current Chief Commercial Officer, has been promoted to Chief Executive Officer and Director, effective immediately. Brian Blaser has stepped down from the positions of President, Chief Executive Officer and Director, due to personal matters.

MENLO PARK, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to advancing health equity and outcomes through the delivery of accurate infect

MENLO PARK, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care (the Company), announced that the Companys Board of Directors has granted an inducement award to Brian Blaser, the Companys newly appointed Chief Executive Officer. The inducement award was granted pursuant to the Companys 2021 Inducement Plan (the Inducement Plan) as an inducement material to Mr. Blaser entering into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4).

Zacks Investment Research upgraded shares of Talis Biomedical (NASDAQ:TLIS) from a sell rating to a hold rating in a report published on Friday morning, Zacks.com reports. According to Zacks, Talis Biomedical Corporation engaged in developing and commercializing products for infectious diseases at the point-of-care. The company involved in developing the Talis One platform, a compact, []

Talis Biomedical Co. (NASDAQ:TLIS) Director Bros. Advisors Lp Baker acquired 50,000 shares of Talis Biomedical stock in a transaction that occurred on Thursday, November 18th. The shares were purchased at an average cost of $4.37 per share, for a total transaction of $218,500.00. The transaction was disclosed in a legal filing with the SEC, which []

Talis Biomedical (NASDAQ:TLIS) posted its quarterly earnings data on Sunday. The company reported ($1.49) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($1.40) by ($0.09), MarketWatch Earnings reports. Shares of NASDAQ:TLIS traded down $0.68 during midday trading on Tuesday, reaching $5.12. 4,063 shares of the companys stock were exchanged, compared to its []

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Kezar Life Sciences Reports Positive Interim Phase 2 Data For Lupus Nephritis Treatment Candidate Keza

TLIS earnings call for the period ending September 30, 2021.

TLIS earnings call for the period ending September 30, 2021.